Zevra Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Zevra Therapeutics' 2024 10-K filing highlights the FDA approval and commercial launch of MIPLYFFA, along with financial results and strategic shifts towards rare disease focus.
NASDAQ
10-K: Zevra Therapeutics Outlines Share Structure, Warrants, and Anti-Takeover Measures in SEC Filing
Zevra Therapeutics details its capital structure, outstanding warrants, and anti-takeover provisions in a recent SEC filing, providing investors with a comprehensive overview of its securities.